Vertex's Journavx got FDA approval for acute pain but faces adoption challenges: variable efficacy vs opioids, generic competition, and entrenched prescriber habits limit near-term potential ...

Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' (VRTX.O), opens new tab drug to treat acute pain, the health regulator said on Thursday, offering a ...

BOSTON, January 12, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the ...

Vertex Pharmaceuticals is hoping to build upon its existing rare blood disease treatment portfolio, teaming up with Orna Therapeutics’ ReNAgade in efforts to develop next-gen gene therapies for ...

Vertex has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past, it’s that there are many kinds of pain.

Get the Real Story Behind Every Major Earnings Report RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients ...

MANILA, Philippines — The Social Security System (SSS) on Tuesday said that its latest contribution rate hike and increase in the Monthly Salary Credit (MSC) will enhance members’ benefits and ...

MANILA, Philippines — Despite calls to suspend the Social Security System (SSS) contribution hike, the pension firm is set to implement the increase this January. SSS President and Chief ...

"The SSS, given its current financial position, is apparently capable of deferring the increase, with the National Government perhaps stepping in to provide funds to [meet] the pension system's ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy ...